High-throughput screening assays to discover small-molecule inhibitors of protein interactions

Current Drug Discovery Technologies

Volumn 5, Issue 3, 2008, Pages 190-199

  Colas, Pierre ^a  

^a Protein Phosphorylation and Human Disease Group   (France)

Author keywords

Drug discovery; High throughput screening; Protein interactions; Two hybrid

Indexed keywords

PROTEIN INHIBITOR; PROTEIN INTERACTION INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BIOTECHNOLOGY; COMPLEX FORMATION; DRUG DESIGN; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; QUANTITATIVE ASSAY; REPRODUCIBILITY; TECHNIQUE; TWO HYBRID SYSTEM;

ANIMALS; DRUG DISCOVERY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MOLECULAR STRUCTURE; PROTEIN INTERACTION MAPPING; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 51349160681     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016308785739875     Document Type: Article

References (63)

1. Aloy P.: Shaping the future of interactome networks. Genome Biol. 8 (10), 316, (2007).
2. Schreiber S.L.: The small-molecule approach to biology. Chemical Engineering News 81 (9), 51, (2003).
3. Chakrabarti P., Janin J.: Dissecting protein-protein recognition sites. Proteins 47 (3), 334, (2002).
4. Bogan A. A., Thorn K.S.: Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280(1), 1, (1998).
5. Arkin M.R., Wells J.A.: Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3 (4), 301, (2004).
6. Boger D.L., Goldberg J., Silletti S., Kessler T., Cheresh D.A.: Identification of a novel class of small-molecule antiangiogenie agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3). J. Am. Chem. Soc. 123 (7), 1280, (2001).
7. Silletti S., Kessler T., Goldberg J., Boger D.L., Cheresh D.A.: Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl. Acad. Sci. USA 98(1), 119, (2001).
8. Ambroise Y., Yaspan B., Ginsberg M.H., Boger D.L.: Inhibitors of cell migration that inhibit intracellular paxillin/alpha4 binding: a well-documented use of positional scanning libraries. Chem. Biol. 9 (11), 1219, (2002).
9. Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., Bruseo C., Wood A.W., et al.: Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 5 (1), 91, (2004).
10. Owolabi J.B., Rizkalla G., Tehim A., Ross G.M., Riopelle R.J., Kamboj R., Ossipov M., Bian D., et al.: Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J. Pharmacol. Exp. Ther. 289 (3), 1271, (1999).
11. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., et al.: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA 96 (10), 5698, (1999).
12. Nasir M.S., Jolley M.E.: Fluorescence polarization: an analytical tool for immunoassay and drug discovery. Comb. Chem. High Throughput Screen. 2 (4), 177, (1999).
13. Degterev A., Lugovskoy A., Cardone M., Mulley B., Wagner G., Mitchison T., Yuan J.: Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol. 3 (2), 173, (2001).
14. Kenny C.H., Ding W., Kelleher K., Benard S., Dushin E.G., Sutherland A.G., Mosyak L., Kriz R., et al.: Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction. Anal. Biochem. 323 (2), 224, (2003).
15. Roehrl M.H.A., Kang S., Aramburu J., Wagner G., Rao A., Hogan P.G.: Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc. Natl. Acad. Sci. USA 101 (20), 7554, (2004).
16. Moerke N.J., Aktas H., Chen H., Cantel S., Reibarkh M.Y., Fahmy A., Gross J.D., Degterev A., et al.: Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128 (2), 257, (2007).
17. Berg T., Cohen S.B., Desharnais J., Sonderegger C., Maslyar D.J., Goldberg J., Boger D.L., Vogt P.K.: Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA 99 (6), 3830, (2002).
18. Bergendahl V., Heyduk T., Burgess R.R.: Luminescence resonance energy transfer-based high-throughput screening assay for inhibitors of essential protein-protein interactions in bacterial RNA polymerase. Appl. Environ. Microbiol. 69 (3), 1492, (2003).
19. Comley J.: TR-FRET based assays - getting better with age. Drug Discovery World, Spring, 22, (2006).
20. Kadkhodayan S., Elliott L.O., Mausisa G., Wallweber H.A., Deshayes K., Feng B., Fairbrother W.J.: Evaluation of assay technologies for the identification of protein-peptide interaction antagonists. Assay Drug Dev. Technol. 5 (4), 501, (2007).
21. Sehr P., Pawlita M., Lewis J.: Evaluation of different glutathione S-transfe rase-tagged protein captures for screening E6/E6AP interaction inhibitors using AlphaScreen. Biomol. Screen. 12 (4), 560, (2007).
22. Karlsson R.: SPR for molecular interaction analysis: a review of emerging application areas. J. Mol. Recognit. 17 (3), 151, (2004).
23. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (5659), 844, (2004).
24. Savchenko A., Kashuba E., Kashuba V., Snopok B.: Imaging technique for the screening of protein-protein interactions using scattered light under surface plasmon resonance conditions. Anal. Chem. 79 (4), 1349, (2007).
25. Jung S.O., Ro H.S., Kho B.H., Shin Y.B., Kim M.G., Chung B.H.: Surface plasmon resonance imaging-based protein arrays for high-throughput screening of protein-protein interaction inhibitors. Proteomics 5 (17), 4427, (2005).
26. Cooper M.A.: Optical biosensors: where next and how soon? Drug Disc. Today 11 (23/24), 1061, (2006).
27. Hajduk P.J., Gerfin T., Boehlen J.M., Haberli M., Marek D., Fesik S.W.: High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42 (13), 2315, (1999).
28. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., et al.: An inhibitor of Be 1-2 family proteins induces regression of solid tumours. Nature 435 (7042), 677, (2005).
29. Best J.L., Amezcua C.A., Mayr B., Flechner L., Murawsky C.M., Emerson B., Zor T., Gardner K.H., et al.: Identification of small-molecule antagonists that inhibit an activator: coactivator interaction. Proc. Natl. Acad. Sci. USA 101 (51), 17622, (2004).
30. Zehender H., Mayr L.M.: Application of mass spectrometry technologies for the discovery of low-molecular weight modulators of enzymes and protein-protein interactions. Curr. Opin. Chem. Biol. 11 (5), 511, (2007).
31. Kato-Stankiewicz J., Hakimi I., Zhi G., Zhang J., Serebriiskii I., Guo L., Edamatsu H., Koide H., et al.: Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc. Natl. Acad. Sci. USA 99 (22), 14398, (2002).
32. Yin X., Giap C., Lazo J.S., Prochownik E.V.: Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22 (40), 6151, (2003).
33. Nieuwenhuijsen B.W., Huang Y., Wang Y., Ramirez F., Kalgaonkar G., Young K.H.: A dual luciferase multiplexed high-throughput screening platform for protein-protein interactions. J. Biomol. Screen. 8 (6), 676, (2003).
34. Young K., Lin S., Sun L., Lee E., Modi M., Hellings S., Husbands M., Ozenberger B., et al.: Identification of a calcium channel modulator using a high throughput yeast two-hybrid screen. Nat. Biotechnol. 16 (10), 946, (1998).
35. Huang J., Schreiber S.L.: A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. Proc. Natl. Acad. Sci. USA 94 (25), 13396, (1997).
36. Gunde T., Tanner S., Auf der Maur A., Petrascheck M., Barberis A.: Quenching accumulation of toxic galactose-1-phosphate as a system to select disruption of protein-protein interactions in vivo. Biotechniques 37 (5), 844, (2004).
37. Hirst M., Ho C., Sabourin L., Rudnicki M., Penn L., Sadowski I.: A two- hybrid system for transactivator bait proteins. Proc. Natl. Acad. Sci. USA 98 (15), 8726, (2001).
38. Joshi P.B., Hirst M., Malcolm T., Parent J., Mitchell D., Lund K., Sadowski I.: Identification of protein interaction antagonists using the repressed trans-activator two-hybrid system. Biotechniques 42 (5), 635, (2007).
39. Zhao H.F., Kiyota T., Chowdhury S., Purisima E., Banville D., Konishi Y., Shen S.H.: A mammalian genetic system to screen for small molecules capable of disrupting protein-protein interactions. Anal. Chem. 76 (10), 2922, (2004).
40. Ehrhard K.N., Jacoby J.J., Fu X.Y., Jahn R., Dohlman H.G.: Use of G-protein fusions to monitor integral membrane protein-protein interactions in yeast. Nat. Biotechnol. 18 (10), 1075, (2000).
41. Aronheim A., Zandi E., Hennemann H., Elledge S.J., Karin M.: Isolation of an AP-1 repressor by a novel method for detecting protein- protein interactions. Mol. Cell. Biol. 17 (6), 3094, (1997).
42. Broder Y.C., Katz S., Aronheim A.: The ras recruitment system, a novel approach to the study of protein-protein interactions. Curr. Biol. 8 (20), 1121, (1998).
43. Hubsman M., Yudkovsky G., Aronheim A.: A novel approach for the identification of protein-protein interaction with integral membrane proteins. Nucleic Acids Res. 29 (4), E18, (2001).
44. Stagljar I., Korostensky C., Johnsson N., te Heesen S.: A genetic system based on split-ubiquitin for the analysis of interactions between membrane proteins in vivo. Proc. Natl. Acad. Sci. USA 95 (9), 5187, (1998).
45. Wittke S., Lewke N., Muller S., Johnsson N.: Probing the molecular environment of membrane proteins in vivo. Mol. Biol. Cell 10 (8), 2519, (1999).
46. Fetchko M., Auerbach D., Stagljar I.: Yeast genetic methods for the detection of membrane protein interactions: potential use in drug discovery. BioDrugs 17 (6), 413, (2003).
47. Eyckerman S., Lemmens I., Catteeuw D., Verhee A., Vandekerckhove J., Lievens S., Tavernier J.: Reverse MAPPIT: screening for protein-protein interaction modifiers in mammalian cells. Nat. Methods 2 (6), 427, (2005).
48. Michnick S.W., Ear P.H., Manderson E.N., Remy I., Stefan E.: Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nat. Rev. Drug Discov. 6 (7), 569, (2007).
49. Buttner F.H., Kumpf R., Menzel S., Reulle D., Valler M.J.: Evaluation of the InteraX system technology in a high-throughput screening environment. J. Biomol. Screen. 10 (5), 485, (2005).
50. Lundholt B.K., Heydorn A., Bjorn S.P., Praestegaard M.: A simple cell-based HTS assay system to screen for inhibitors of p53-Hdm2 protein-protein interactions. Assay Drug Dev. Technol. 4 (6), 679, (2006).
51. Baines I.C., Colas P.: Peptide aptamers as guides for small molecule drug discovery. Drug Disc. Today 11, 334, (2006).
52. Colas P.: The eleven-year switch of peptide aptamers. J. Biol. 7, 2, (2008).
53. Pamonsinlapatham P., Hadj-Slimane R., Raynaud F., Bickle M., Corneloup C., Barthelaix A., Lepelletier Y., Mercier P., et al.: A RasGAP SH3 peptide aptamer inhibits RasGAP-Aurora interaction and induces caspase-independent tumor cell death. PlosONE in press.
54. Bardou C. Borie C., Bickle M., Rudkin B.B., Colas P.: In Nucleic acids and peptide aptamers, Humana Press Ltd, Totowa, in press.
55. Mazuc E., Villoutreix B., Malbec O., Roumier T., Fleury S., Leonetti J.P., Dombrowicz D., Daeron M. et al.: A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally. J. Allergy Clin. Immunol. 122 (1), 188, (2008).
56. Mayer G., Jenne A.: Aptamers in research and drug development. BioDrugs 18 (6), 351, (2004).
57. Yamazaki S., Tan L., Mayer G., Hartig J.S., Song J.N., Reuter S., Restle T., Laufer S.D., et al.: Aptamer displacement identifies alternative small-molecule target sites that escape viral resistance. Chem. Biol. 14 (7). 804, (2007).
58. Jessen T.: High-throughput screening brings in the crops. Drug Disc. Today 5 (12 Suppl 1), 49, (2000).
59. Trosset J.Y., Dalvit C., Knapp S., Fasolini M., Veronesi M., Mantegani S., Gianellini L.M., Catana C., et al.: Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins 64 (1), 60, (2006).
60. Zhong S., Macias A.T., MacKerell A.D., Jr.: Computational identification of inhibitors of protein-protein interactions. Curr. Top. Med. Chem. 7 (1), 63, (2007).
61. Shuttleworth S.J., Connors R.V., Fu J., Liu J., Lizarzaburu M.E., Qiu W., Sharma R., Wanska M., et al.: Design and synthesis of protein superfamily-targeted chemical libraries for lead identification and optimization. Curr. Med. Chem. 12 (11), 1239, (2005).
62. Fry D.C.: Protein-protein interactions as targets for small molecule drug discovery. Biopolymers 84 (6), 535, (2006).
63. McMillan K., Adler M., Auld D.S., Baldwin J.J., Blasko E., Browne L.J., Chelsky D., Davey D., et al.: Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl. Acad. Sci. USA 97 (4), 1506, (2000).